Differential Gene Expression Profiles of PPP2R5C -siRNA-Treated Malignant T Cells
Open Access
- 1 October 2013
- journal article
- research article
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 32 (10) , 573-581
Abstract
Recently, alterations in the expression pattern of PPP2R5C associated with malignant transformation have been characterized, and PPP2R5C overexpression was demonstrated in leukemias. To confirm the role of PPP2R5C in proliferation and its molecular mechanism, three PPP2R5C-siRNAs and a scrambled nonsilencing siRNA control were used to treat Molt-4 and Jurkat T cells. After nucleofection, PPP2R5C expression and biological consequences based on a highly efficient and specific PPP2R5C-siRNA were demonstrated by qRT-PCR, CCK-8 assay, Annexin V/PI, and flow cytometry. The global gene expression profile of PPP2R5C-siRNA-treated Jurkat T cells was established. A significant reduction in the PPP2R5C mRNA level was observed at 24 to 72 h in Molt-4 and Jurkat T cells with all of the PPP2R5C-siRNAs. The proliferation rate of Molt-4 and Jurkat T cells transfected with different PPP2R5C-siRNAs was significantly decreased at 72 h compared with the control (pPPP2R5C-siRNA2 was used to treat Jurkat T cells for gene expression profile analysis. In total, 439 genes were upregulated, and 524 genes were downregulated at least twofold in PPP2R5C-siRNA-treated Jurkat T cells. Changes in signaling pathway genes closely related to the TCR, Wnt, calcium, MAPK, and p53 signaling pathways were observed. In conclusion, the suppression of PPP2R5C by RNA interference could effectively inhibit the proliferation of leukemic T cells, the PPP2R5C-siRNA treatment altered gene expression profiles, and the differential expression of the glycogen synthase kinase 3 beta (GSK-3β), ataxia telangiectasia mutated (ATM), and Mdm2 p53 binding protein homolog (MDM2) genes may play an important role in the effects of PPP2R5C knockdown in Jurkat T cells. Knocking down PPP2R5C using siRNA altered downstream gene expression, and was associated with decreased proliferation of Jurkat cells. Among the differentially expressed genes are GSK-3β, ATM, and Mdm2 p53 binding protein homolog.Keywords
This publication has 51 references indexed in Scilit:
- The ATM protein kinase and cellular redox signaling: beyond the DNA damage responseTrends in Biochemical Sciences, 2012
- Gene Expression Profiling-Based Identification of CD28 and PI3K as New Biomarkers for Chronic Graft-Versus-Host DiseaseDNA and Cell Biology, 2011
- Functions of B56-containing PP2As in major developmental and cancer signaling pathwaysLife Sciences, 2010
- Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer ImmunotherapyClinical Cancer Research, 2010
- The B56γ3 Regulatory Subunit of Protein Phosphatase 2A (PP2A) Regulates S Phase-specific Nuclear Accumulation of PP2A and the G1 to S TransitionJournal of Biological Chemistry, 2010
- A B56γ mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2AOncogene, 2010
- Wnt/β-Catenin Signaling: Components, Mechanisms, and DiseasesDevelopmental Cell, 2009
- Serine 15 Phosphorylation of p53 Directs Its Interaction with B56γ and the Tumor Suppressor Activity of B56γ-Specific Protein Phosphatase 2AMolecular and Cellular Biology, 2008
- A specific PP2A regulatory subunit, B56γ, mediates DNA damage‐induced dephosphorylation of p53 at Thr55The EMBO Journal, 2007
- Diversity of LEF/TCF action in development and diseaseOncogene, 2006